Literature DB >> 8593900

Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy.

I Barajon1, M Bersani, M Quartu, M Del Fiacco, G Cavaletti, J J Holst, G Tredici.   

Abstract

Dorsal root ganglia (DRG) neuronopathy was induced in rats by chronic treatment (2 mg/kg twice a week for nine injections) with the antineoplastic drug cisplatin. Morphological alterations and changes in peptide [calcitonin gene-related peptide (CGRP), substance P, galanin (Gal), and somatostatin] concentration were studied in the DRG, the spinal cord, and the sciatic nerve. Peptide concentration was increased in DRG neurons, with CGRP and Gal showing the highest increase. Conversely, in the sciatic nerve there was a general decrease in peptide content. In DRG a reduction in the nuclear, cytoplasmic, and nucleolar areas of primary sensory neurons was evident and was accompanied by clear-cut aspects of nucleolar structural damage. In peripheral nerves only extensive morphometric determinations could evidence a reduction in nerve conduction velocities and impairment in pain detection and coordination. Some of the nerve fibers presented axonal and adaxonal accumulations, suggesting the presence of an axonopathy. These results confirm that DRG cells are the primary target of cisplatin-induced neurotoxicity. Milder alterations can be detected in peripheral nerves. The increase in peptide concentration in DRG is probably due to cisplatin-related damage to the axonal transport system rather than to an increased synthesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8593900     DOI: 10.1006/exnr.1996.0050

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  15 in total

1.  Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews.

Authors:  Julie L Eiseman; Jan H Beumer; Lora H Rigatti; Sandra Strychor; Kelly Meyers; Samuel Dienel; Charles C Horn
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-15       Impact factor: 3.333

2.  Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate.

Authors:  F M Boyle; H R Wheeler; G M Shenfield
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

3.  Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration.

Authors:  G Tredici; S Tredici; D Fabbrica; C Minoia; G Cavaletti
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

4.  APE1, the DNA base excision repair protein, regulates the removal of platinum adducts in sensory neuronal cultures by NER.

Authors:  Hyun-Suk Kim; Chunlu Guo; Eric L Thompson; Yanlin Jiang; Mark R Kelley; Michael R Vasko; Suk-Hee Lee
Journal:  Mutat Res       Date:  2015-06-26       Impact factor: 2.433

5.  Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy.

Authors:  Juan P Cata; Han-Rong Weng; Patrick M Dougherty
Journal:  Brain Res       Date:  2008-07-15       Impact factor: 3.252

Review 6.  Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy.

Authors:  Jordi Bruna; Paola Alberti; Aina Calls-Cobos; Martial Caillaud; M Imad Damaj; Xavier Navarro
Journal:  Exp Neurol       Date:  2019-12-15       Impact factor: 5.330

7.  Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle.

Authors:  J S Gill; A J Windebank
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

8.  Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors.

Authors:  Jan Oldenburg; Sophie D Fosså; Alv A Dahl
Journal:  Qual Life Res       Date:  2006-06       Impact factor: 3.440

9.  Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice.

Authors:  Hichem Bouchenaki; Aurore Danigo; Amandine Bernard; Flavien Bessaguet; Laurence Richard; Franck Sturtz; David Balayssac; Laurent Magy; Claire Demiot
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

10.  A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy.

Authors:  Lauren E Ta; James D Schmelzer; Allan J Bieber; Charles L Loprinzi; Gary C Sieck; Jill D Brederson; Philip A Low; Anthony J Windebank
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.